CRH: The Stress Peptide Behind Cortisol

Hypothalamic Releasing Hormones

41 amino acids

Corticotropin-releasing hormone is a 41-amino-acid peptide synthesized in the hypothalamus that initiates the entire cortisol stress response. CRH acts through two receptor subtypes with opposing effects: CRF1 drives anxiety while CRF2 may promote stress recovery.

Reul & Holsboer, Current Opinion in Pharmacology, 2002

Reul & Holsboer, Current Opinion in Pharmacology, 2002

View as image

Every stress response begins with a single peptide. When the brain detects a threat, neurons in the paraventricular nucleus of the hypothalamus release corticotropin-releasing hormone (CRH), a 41-amino-acid peptide that travels through the portal blood system to the anterior pituitary. There, CRH triggers the release of adrenocorticotropic hormone (ACTH), which travels through the bloodstream to the adrenal cortex and stimulates cortisol production. This sequence, the hypothalamic-pituitary-adrenal (HPA) axis, is the body's primary endocrine stress response, and CRH is its initiating signal. For a broader look at how hypothalamic peptides control the endocrine system, see our overview of the hypothalamic-pituitary axis.

CRH was isolated and sequenced in 1981 by Wylie Vale and colleagues at the Salk Institute. In the four decades since, it has become one of the most studied neuropeptides in neuroscience, with direct implications for understanding anxiety, depression, addiction, and inflammatory disease. This article examines CRH's biology, its receptor system, and the repeated attempts to translate CRH research into psychiatric drugs. For context on how the parent cluster covers the master reproductive peptide, see our overview of GnRH.

How CRH Launches the Cortisol Cascade

The HPA axis activation sequence occurs within minutes. Stress-responsive neurons in the paraventricular nucleus (PVN) of the hypothalamus release CRH into the hypophysial portal vessels, the specialized blood supply connecting the hypothalamus to the anterior pituitary. CRH binds to CRF1 receptors on corticotrope cells in the anterior pituitary, stimulating them to cleave proopiomelanocortin (POMC) into ACTH and beta-endorphin, which are co-released into the systemic circulation.

ACTH reaches the adrenal cortex within minutes and rapidly stimulates cortisol biosynthesis from cholesterol. Cortisol then acts on virtually every tissue in the body: it mobilizes glucose, suppresses immune function, increases cardiovascular tone, and sharpens cognitive focus. This is the fight-or-flight metabolic shift.

The system self-regulates through negative feedback. Cortisol binds to glucocorticoid receptors in both the hypothalamus and the pituitary, suppressing further CRH and ACTH release. This feedback loop normally limits the stress response to minutes or hours. When the feedback loop fails, as in Cushing's disease or chronic stress, sustained cortisol elevation produces the metabolic, immune, and psychiatric consequences associated with pathological stress.

CRH does not act alone. Vasopressin, released from the same PVN neurons, acts synergistically with CRH to amplify ACTH secretion. The ratio of CRH to vasopressin release shifts with the type and chronicity of the stressor, fine-tuning the magnitude and duration of the cortisol response.^[1]

Two Receptors, Opposing Roles

The CRH receptor system comprises two subtypes with distinct pharmacological profiles and anatomical distributions.

CRF1 receptors are expressed throughout the cerebral cortex, cerebellum, hippocampus, amygdala, and anterior pituitary. CRF1 activation produces anxiety-like behavior in animal models and mediates the neuroendocrine stress response. Genetic deletion of CRF1 in mice produces reduced anxiety and impaired HPA axis activation.^[2]

CRF2 receptors exist in two splice variants (CRF2alpha and CRF2beta) with more restricted distribution: lateral septum, ventromedial hypothalamus, and peripheral tissues including heart, skeletal muscle, and gastrointestinal tract. CRF2 activation appears to have anxiolytic (anxiety-reducing) effects in some contexts, potentially facilitating stress recovery and coping. The natural ligands for CRF2 include urocortin II and urocortin III, two related peptides that are selective CRF2 agonists.^[1]

A CRH-binding protein (CRH-BP) adds a third layer of regulation. CRH-BP sequesters free CRH in the circulation and brain, modulating the amount of peptide available to activate receptors. The balance between CRH, CRH-BP, and the two receptor subtypes creates a system far more complex than a simple on/off stress switch.^[3]

The Molecular Recognition of CRH

The structural biology of CRH-receptor interaction was clarified by a 2008 study that mapped how CRH binds to CRF1 through a two-step mechanism. The C-terminal alpha-helix of CRH first docks to the N-terminal extracellular domain of CRF1, providing binding affinity. The N-terminal residues of CRH then contact the receptor's transmembrane core, triggering the conformational change that activates intracellular G-protein signaling.^[4]

This two-step model explains why truncated CRH analogs can serve as receptor antagonists: peptides retaining the C-terminal binding helix but lacking the N-terminal activation domain bind CRF1 without activating it, blocking the receptor. Astressin, a cyclic CRH antagonist, was designed using this principle, and structure-activity studies identified the minimal peptide sequence retaining antagonist activity at both CRF1 and CRF2.

CRH Beyond the Brain: Peripheral Effects

CRH is not confined to the hypothalamus. CRH and its receptors are expressed in immune cells, gut, skin, joints, and the reproductive tract, where they have direct local effects independent of the HPA axis.

Immune System and Pain

A landmark 1994 study demonstrated that CRH triggers immune cells in inflamed tissue to release opioid peptides (beta-endorphin, met-enkephalin, dynorphin), producing local pain relief at the site of inflammation. This effect was blocked by naloxone and anti-opioid antibodies, confirming that CRH-induced analgesia operates through peripheral opioid mechanisms.^[5]

Inflammation

A 2005 review documented that CRH family peptides have direct pro-inflammatory (via CRF1) and anti-inflammatory (via CRF2) effects on immune cells, gut epithelium, and skin, independent of cortisol. CRH released locally in the gut is implicated in stress-induced intestinal inflammation and irritable bowel syndrome. In the skin, CRH from keratinocytes and mast cells contributes to stress-related dermatitis, psoriasis flares, and urticaria.^[6]

CRH in Psychiatric Disorders

The hypothesis that CRH overactivity drives anxiety and depression has been one of the most productive ideas in biological psychiatry.

Depression and Anxiety

Depressed patients consistently show elevated CRH levels in cerebrospinal fluid, enlarged adrenal glands (reflecting chronic ACTH stimulation), and impaired cortisol feedback. Intracerebroventricular CRH injection in animals produces a syndrome resembling depression: reduced appetite, disrupted sleep, decreased sexual behavior, and increased anxiety. CRF1-mediated hypersignaling in the brain has been identified in patients with anxiety and depressive disorders.^[2]

Chronic Stress and Brain Changes

A 2008 study mapped how chronic psychosocial stress alters CRH peptide levels in specific brain regions. Chronically stressed animals showed altered CRH content in the paraventricular nucleus and central extended amygdala, with changes correlating directly with anxiety-like behavior. These findings demonstrate that sustained stress physically reprograms the brain's CRH circuits, providing a neurochemical basis for stress-induced anxiety disorders.^[7]

Addiction

The CRF system is now recognized as a key mediator of the stress component of drug addiction. A 2005 review documented that CRF1 activation drives withdrawal-induced anxiety in cannabis, nicotine, and alcohol dependence. During abstinence, CRH levels surge in the extended amygdala, producing the dysphoric state that motivates relapse. CRF1 antagonists reduce withdrawal-induced anxiety and self-administration in animal models of all three substances.^[8]

The Failed Promise of CRF1 Antagonists

Given the strong preclinical rationale, pharmaceutical companies invested heavily in developing CRF1 receptor antagonists for depression and anxiety.

Preclinical Success

CP-154,526, the first selective non-peptide CRF1 antagonist, reduced anxiety across multiple animal models (elevated plus maze, defensive withdrawal, fear-potentiated startle) without the sedation associated with benzodiazepines. It also showed antidepressant activity and normalized stress-induced HPA axis hyperactivation.^[9] Multiple pharmaceutical companies developed their own CRF1 antagonists based on these results.

Clinical Disappointment

A 2010 review documented the trajectory of CRF1 antagonist development. Several compounds reached Phase II/III clinical trials for major depression, generalized anxiety disorder, and social anxiety disorder. The results were mixed: some trials showed modest efficacy, others showed no separation from placebo. Tolerability issues, including hepatotoxicity with some compounds, further complicated development. As of 2026, no CRF1 antagonist has achieved regulatory approval for any psychiatric indication.^[10]

The failure of CRF1 antagonists in clinical trials illustrates a recurring challenge in psychiatric drug development: animal models of anxiety and depression do not reliably predict human clinical efficacy. The CRH-driven stress response is clearly involved in psychiatric disorders, but blocking CRF1 alone may not be sufficient to treat conditions with multiple converging pathophysiological mechanisms.

The Urocortin Family: CRH's Relatives

CRH is not the only member of its peptide family. Three related peptides, urocortin 1, urocortin II (stresscopin-related peptide), and urocortin III (stresscopin), share structural homology with CRH but have distinct receptor selectivity.

Urocortin 1 binds both CRF1 and CRF2 with high affinity. Urocortins II and III are selective CRF2 agonists, meaning they activate the "stress recovery" receptor without engaging the "stress activation" CRF1 pathway. This selectivity makes urocortins particularly interesting for understanding the biphasic nature of stress: CRH and urocortin 1 initiate the stress response through CRF1, while urocortins II and III may promote recovery through CRF2.

In the periphery, urocortins are expressed in the heart, where CRF2 activation has cardioprotective effects, and in the gastrointestinal tract, where CRF2 agonism reduces gastric motility and inflammation. The therapeutic potential of selective CRF2 agonists for anxiety, stress-related GI disorders, and cardiac protection remains largely unexplored clinically.

CRH and Other Hypothalamic Peptides

CRH does not operate in isolation within the hypothalamus. It interacts with multiple peptide systems that collectively regulate the body's hormonal environment.

CRH neurons in the PVN receive inhibitory input from neuropeptide Y (NPY) neurons, which suppress CRH release and promote anxiolysis. The CRH-NPY balance is sometimes described as a "stress thermostat," with CRH driving arousal and NPY promoting calm. CRH also modulates growth hormone release through intrahypothalamic connections and influences reproductive function by suppressing gonadotropin-releasing hormone (GnRH) secretion during stress, which is the mechanism behind stress-induced amenorrhea and reduced fertility.

The interplay between CRH and vasopressin deserves emphasis. Both peptides are co-expressed in PVN neurons and co-released during stress, but their relative contributions shift depending on context. Acute, novel stressors favor CRH-dominant release, while chronic or repeated stressors shift toward vasopressin-dominant release. This shift may explain why chronic stress produces different endocrine and behavioral patterns than acute stress.

For more on the other hypothalamic releasing hormones, see our articles on GHRH and growth hormone release and TRH and thyroid control.

The Bottom Line

CRH is the initiating peptide of the cortisol stress response, acting through two receptor subtypes with opposing effects on anxiety. Four decades of research have established CRH's role in depression, anxiety, addiction, and peripheral inflammation. CRF1 antagonists showed strong preclinical promise but failed to translate into approved psychiatric drugs, highlighting the gap between animal models and human clinical efficacy. CRH's peripheral effects on immune cells, gut, and skin demonstrate that this "stress peptide" has functions far beyond the HPA axis. Understanding CRH biology remains essential for any attempt to pharmacologically modulate the stress response.

Frequently Asked Questions

What does CRH do in the body?

CRH (corticotropin-releasing hormone) is a 41-amino-acid peptide released from the hypothalamus that initiates the cortisol stress response. It triggers ACTH release from the pituitary, which stimulates cortisol production from the adrenal glands. CRH also has direct effects on immune cells, gut, and skin through local CRH receptors independent of the cortisol pathway.

Is CRH linked to anxiety and depression?

Yes. Depressed patients show elevated CRH in cerebrospinal fluid, and CRF1 receptor overactivation is associated with anxiety and depressive disorders. Chronic stress reprograms brain CRH circuits, increasing CRH levels in the amygdala. CRF1 antagonists reduced anxiety in animal models, though clinical trials in humans for depression and anxiety have not produced approved drugs.

What is the difference between CRF1 and CRF2 receptors?

CRF1 receptors are widely expressed in the brain and drive anxiety-like behavior, fear responses, and HPA axis activation. CRF2 receptors have more restricted distribution and appear to promote stress recovery and anxiolysis. Their natural ligands include urocortin II and III. The two receptor subtypes have opposing effects on anxiety, making the CRH system more nuanced than a simple stress on/off switch.

Why did CRF1 antagonist drugs fail?

CRF1 antagonists showed strong efficacy in animal models of anxiety and depression but produced mixed results in human clinical trials, with some compounds failing to separate from placebo. Contributing factors include the limitations of animal models for predicting human psychiatric drug response, the complexity of depression as a multi-mechanism disease, and tolerability issues (including hepatotoxicity) with some compounds.

Does CRH affect the immune system?

Yes. CRH triggers immune cells at inflammation sites to release opioid peptides (beta-endorphin, enkephalin, dynorphin) that produce local pain relief. CRH also has direct pro-inflammatory effects through CRF1 receptors and anti-inflammatory effects through CRF2 receptors on immune cells, gut tissue, and skin. Stress-induced CRH release in the gut contributes to IBS symptoms.

How does CRH relate to addiction?

CRH mediates the stress component of substance dependence. During withdrawal from cannabis, nicotine, or alcohol, CRH levels surge in the extended amygdala, producing anxiety and dysphoria that drive relapse. CRF1 receptor activation during abstinence creates a negative reinforcement cycle where substance use temporarily relieves CRH-driven distress, perpetuating the addiction.